Trials / Terminated
TerminatedNCT02324491
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Weight Reduction, Glycemic Control, Safety, and Tolerability
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Zafgen, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adult subjects with type 2 diabetes mellitus.
Detailed description
Phase 2, randomized, double-blind, placebo-controlled, parallel dose arms study with 12-month randomized treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZGN-440 for Injectable Suspension | Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks. |
| DRUG | ZGN-440 Placebo for Injectable Suspension | Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks. |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2014-12-24
- Last updated
- 2016-01-06
Locations
16 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT02324491. Inclusion in this directory is not an endorsement.